NCT05542303View on ClinicalTrials.gov

A Safety, Tolerability and Pharmacokinetics Study of ZB001 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

October 16, 2022

Primary Completion Date

April 4, 2023

Study Completion Date

April 4, 2023

Conditions
Healthy Volunteers
Interventions
DRUG

ZB001 for injection

Dose Cohort1 (3mg/kg) ZB001 of single IV injection

DRUG

ZB001 for injection

Dose Cohort2 (10mg/kg) ZB001 of single IV injection

DRUG

ZB001 for injection

Dose Cohort3 (20mg/kg) ZB001 of single IV injection

Trial Locations (1)

200030

Shanghai Mental Health Center, Shanghai

All Listed Sponsors
lead

Zenas BioPharma (USA), LLC

INDUSTRY